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Abstract
Spinal cord injury (SCI) research is a data-rich field that aims to identify the biological mechan-
isms resulting in loss of function and mobility after SCI, as well as develop therapies that pro-
mote recovery after injury. SCI experimental methods, data and domain knowledge are locked
in the largely unstructured text of scientific publications, making large scale integration with
existing bioinformatics resources and subsequent analysis infeasible. The lack of standard re-
porting for experiment variables and results also makes experiment replicability a significant
challenge. To address these challenges, we have developed RegenBase, a knowledge base of
SCI biology. RegenBase integrates curated literature-sourced facts and experimental details,
raw assay data profiling the effect of compounds on enzyme activity and cell growth, and struc-
tured SCI domain knowledge in the form of the first ontology for SCI, using Semantic Web rep-
resentation languages and frameworks. RegenBase uses consistent identifier schemes and
data representations that enable automated linking among RegenBase statements and also to
other biological databases and electronic resources. By querying RegenBase, we have identi-
fied novel biological hypotheses linking the effects of perturbagens to observed behavioral out-
comes after SCI. RegenBase is publicly available for browsing, querying and download.
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Introduction
Spinal cord injury (SCI) is a cause of significant disability
and loss of quality of life. SCI research is an interdisciplin-
ary field concerned with the biological mechanisms under-
lying loss of function and mobility after SCI and the
discovery of therapies to promote the regeneration and re-
pair of damaged neural tissue for functional recovery (1–
6). Rat and mouse models are most commonly used to
study the effects of SCI and responses to experimental
treatments; a number of standard injury types and func-
tional recovery measures have been developed for this pur-
pose. Despite these advances, experiment replicability
remains a significant challenge, with recent studies report-
ing that less than half of major experimental results are re-
producible in a second laboratory (7, 8).
One reason for this problematic finding is inconsistent
reporting of experimental methods and findings in pub-
lished literature pertaining to SCI. To address this prob-
lem, we recently developed a minimum information
guideline for the SCI research community—Minimum
Information about a Spinal Cord Injury experiment
(MIASCI) (9)—to encourage consistent reporting of all ex-
perimental details of a study. MIASCI includes fields for
describing the model organisms used in a study including
their genotype and phenotype, age, strain and housing en-
vironment, as well as any surgical variables including anes-
thetics used, injury type and severity, instrument used to
administer injury, and post-surgical care. It also allows sci-
entists to describe any perturbagens, cell transplants, or
biomaterials used. Data fields for histology, immunochem-
istry and behavioral observation methods used to assess
outcome measures in the study are also defined. Finally,
MIASCI allows any scientist reporting a study to describe
the primary findings in the form of simple structured asser-
tions consisting of the agent(s) investigated (e.g. a pertur-
bagen or injury type), their target(s) (e.g. axon growth,
behavioral outcomes) and their effect(s).
Another significant barrier to discovery in SCI research
is the lack of comprehensive, large-scale and widely access-
ible electronic resources, similar to the National Center for
Biotechnology Information’s (NCBI) Gene Expression
Omnibus for gene expression data (10), that capture ex-
perimental results from SCI studies and make them avail-
able for subsequent analysis by researchers. The
availability of such resources in other areas of biological
research has proven invaluable for driving new discoveries
that were possible only through analyzing large volumes of
data aggregated from significant numbers of experiments.
This has yet to be achieved for neuroscience (11) and spe-
cifically in SCI research, though recent efforts have demon-
strated the promise of large-scale integrated data resources
in this domain (12). The majority of SCI research findings
remains locked in publications that are human readable
but not available for computational analysis, and are thus
a valuable but largely untapped resource for informatics
driven discovery.
Computational approaches for structuring and integrat-
ing biological data are an integral aspect of modern life sci-
ences research. The breadth and depth of the literature and
the volume of data generated by high throughput experi-
mental methods makes it infeasible for experimental biolo-
gists to manually integrate these data for their own
research. The application of Semantic Web standards and
representation methods (including ontologies and linked
data) has emerged as a promising solution to this synthesis
problem. Recent work has demonstrated that structuring
biological data using a linked data approach enables biolo-
gical discoveries through data integration and the use of
query languages (13–15), whereas the development and
use of ontologies enables formal logic-based reasoning
over biological and medical domain knowledge (16–18).
Our recent work has also demonstrated the utility of a
Semantic Web framework for data-driven hypothesis
evaluation (19, 25) to discover novel aging-related genes in
the model organism Caenorhabditis elegans (20).
We envision a scenario in which an SCI biologist can
simultaneously interrogate relevant available literature,
biological databases and experimental data to, for ex-
ample, identify chemical compounds that improve behav-
ioral outcomes after SCI in model organisms, and inhibit
regulatory kinases in vitro, as well as identify the kinase
targets of these compounds. With this new knowledge, she
is able to hypothesize a possible mechanism by which these
compounds affect behavior after injury and design experi-
ments to test the hypothesis. After she completes these ex-
periments, the data are available to other researchers who
can use these results to design additional experiments (per-
haps in another organism) and make new discoveries.
Eventually, the increase in the pace of such findings can
lead to the development of a therapy that is tested in a
human clinical trial. We have developed RegenBase to cap-
ture domain knowledge, literature-sourced findings, and
experimental data related to SCI in an online, publicly
available resource to enable such a scenario.
Materials and methods
Creating RegenBase required four distinct but related
activities: ontology development, literature curation, data
representation, and data integration. We describe each of
these activities below with illustrative examples. Our guid-
ing motivation for each activity was to create a
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representation of experimental data in the domain of SCI
research that allows querying and data analysis to formu-
late and answer biological questions.
Ontology development
We created the RegenBase Ontology (RB) as a machine-
understandable representation of the design and results of
SCI experiments. We used a combination of automated
and manual approaches for selecting entities to include.
We first used a simple text processing pipeline to identify
frequently mentioned 1–3 word entities from articles
related to SCI research (retrieved by a keyword search of
PubMed—the search terms used are listed in
Supplementary Appendix S1). We manually reviewed the
list of frequently mentioned entities to filter out those not
specific to SCI biology. The remaining concepts became
our preliminary set of classes. We worked with domain ex-
perts to develop the class hierarchy from our initial ‘seed’
classes and extend the ontology with classes representing
aspects of experimental design (e.g. injury types, control
groups, and treatment groups) and experimental outcomes
(e.g. behavioral assays, measures of regeneration). For
each class added, we determined its most appropriate
placement in the RegenBase class hierarchy (adding parent
classes as necessary to achieve a consistent granularity for
all classes) and specified labels and synonyms as well as
human readable definitions. A.C., S.W.A. and U.V. de-
veloped the class hierarchy, labels, and definitions by re-
viewing neuroscience and SCI literature and textbooks in
close collaboration with domain experts V.P.L. and J.L.B.,
in an iterative process including extensive in-person discus-
sions. We also consulted colleagues of V.P.L. and J.L.B.
who have relevant expertise on specific classes, for both
their correct placement in the RegenBase class hierarchy
and their definitions. We used the Prote´ge´ ontology editor
in combination with shared spreadsheets for class labels
and definitions in all phases of ontology development.
Figure 1 shows a subset of classes that were added to the
RB, as well as an example of the labels, synonyms, and
human readable definition for the Basso, Beattie and
Bresnahan score class (‘BBB score’).
We also mapped RB classes to classes in other existing
bio-ontologies whose labels have a lexical match. We first
used the NCBO BioPortal Mappings web service to iden-
tify candidate class matches, and then restricted our set to
those classes that were specific to the mapped ontology
(i.e. not from an imported ontology) and where adding the
mappings to the source ontology did not produce classifi-
cation errors in the RB. The ontologies to which we cur-
rently map RegenBase classes are the Foundational Model
of Anatomy and the Mammalian Phenotype Ontology
(MP). We use the Simple Knowledge Organization Schema
‘is closely related to’ object property to assert RegenBase
class mappings.
Literature curation
Using the MIASCI reporting template (9), domain experts
curated 42 published scientific articles describing experi-
ments studying the effect of kinase inhibitors on recovery
after SCI in rats and mice (Supplementary Appendix S2).
In addition to capturing experimental details specified by
MIASCI, our curators also captured primary findings from
each article and represented these findings using bio-ontol-
ogies and terminologies.
Our curation workflow is a combination of manual and
automated processes. Curators first manually capture ex-
perimental details and primary findings from each article,
which are stored as spreadsheets with a predefined format
(available at the RegenBase website). In this pilot phase, the
primary findings were manually structured by author A.C.
for addition to RegenBase from curator statements, and re-
viewed by authors V.P.L., J.L.B. and S.W.A. for correctness
of content (including assignment of bio-ontology classes to
entities and processes) and structure. An annotation tool de-
veloped by SWA then processed spreadsheets and struc-
tured primary findings corresponding to each article to
create curated statements using classes from the RB as well
as an additional set of bio-ontologies including the MP
(21), Gene Ontology (GO) (22), BioAssay Ontology (BAO)
(23) and Semanticscience Integrated Ontology (SIO) (24).
These ontologies were used because they provide classes
that match concepts frequently used by curators, including
phenotypic outcomes (MP) and biological processes (GO)
described in published experiments. As we curate a broader
range of experiment types and publications, this set will
grow to include additional bio-ontologies as needed.
Our custom annotation tool is designed to process each
set of curated statements from a single article and generate
a machine-understandable representation of these state-
ments. The tool uses rules to process spreadsheets and pro-
duce an event-based representation in Resource
Description Framework (RDF)/Web Ontology Language
(OWL). The rules were developed to produce a consistent
representation of literature-sourced relations between enti-
ties (both individuals and classes) as well as between enti-
ties and data (such as a string label or floating point
number). This representation (described below) facilitates
querying and aggregation across curated articles.
In addition to assigning types to entities using the above
bio-ontologies, we achieved integration with existing data
sources by associating small molecules curated from art-
icles with their PubChem compound identifiers (CIDs),
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and by associating genes and proteins curated from articles
with their NCBI Gene and UniProt identifiers, respectively.
We used the UniProt Retrieve ID/Mapping and PubChem
Power User Gateway services to perform identifier lookups
by gene and protein names/official symbols, and chemical
compound names or simplified molecular-input line-entry
system strings, respectively. We used the MIRIAM registry
and its identifiers.org service to specify all identifiers.
Doing so enables integration with other data sources that
also use this registry through the resolvable URIs it pro-
vides as identifiers, allowing users to retrieve additional
structured information about small molecules, genes and
proteins from their identifiers.org URIs. Our annotation
tool also captures the provenance of all curated statements
including the source publication and the curator of each
statement. Annotations are thus curated reports of events,
and are not interpreted as the ground truth of the event
itself.
Data representation
We designed an event-based representation for the curated
literature-sourced primary findings describing SCI experi-
ments and results. In this representation, experimental
findings are captured as reported biological events meas-
ured by some experimental method. This representation is
flexible (events may involve causative entities, dubbed
‘agents’, as well as the entities acted upon by an agent,
dubbed ‘targets’, or both) and provides a consistent struc-
ture for a variety of experimental findings and their con-
texts (both physical and temporal). Context can include
details such as the magnitude of experimentally observed
effects (e.g. of agents affecting targets) and the timing of
observed events relative to experimental setup. For ex-
ample, SCI experiments often involve causing an injury to
an animal model and measuring response to treatment at
varying time points after injury or after application of a
therapeutic treatment.
Our event representation specifies the type of event
(using the bio-ontologies listed above), as well as the agent,
target, effect, and magnitude of the observed effect of an
agent on a target. The representation may optionally in-
clude a temporal context and a baseline relative to which
an effect is observed. Each agent and target is also typed,
and magnitude is quantified using data type properties and
literal values. Figure 2 illustrates the generic event repre-
sentation we use (Figure 2a) and an example from a cura-
ted article (Figure 2b). Any contextual details are linked to
the event entity, and thus any number of additional con-
texts can be added without changing the underlying repre-
sentation. We link all event statements to their provenance
using the Dublin Core vocabulary, including the source
article, as well as to information about the curation pro-
cess, including the curator and date of curation.
In addition to literature-sourced curation, we populated
RegenBase with a structured representation of experimen-
tal results from two kinds of assays:
• Kinase activity assays that quantify the activity of kin-
ases exposed to different chemical perturbagens relative
to a control.
• Assays that measure the effect of kinase inhibitors on
neurite growth, a well-studied marker of recovery fol-
lowing SCI.
Figure 1. Subset of the new classes added to the RB, showing the human readable label, alternative term and definition for the BBB score class.
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The kinase activity assay data profile the effect of pertur-
bagens on the activities of kinases. Results from three assays
are included in RegenBase: DiscoverRx’s KINOMEscan
binding assay, NanoSyn’s fluorescence assay and Reaction
Biology Corporation’s (RBC) radiometric assay. These assays
measure kinase activity or binding in the presence of a pertur-
bagen at a specified concentration with respect to a control.
The KINOMEscan data consist of dissociation constant (Kd)
values for compound–kinase pairs, which we transformed to
pKd values by first converting the nanomolar Kd values to
molar values, and then calculating the negative log 10 of
each molar Kd value. The NanoSyn and RBC assay data con-
sist of % inhibition values for compound–kinase pairs. In
addition to the raw kinase assay data, we also include data
from a derived activity measure (26) that integrates the re-
sults of multiple kinase assays into a single Kinase Inhibitor
BioActivity (KIBA) value quantifying the effect of a given per-
turbagen on a kinase. We transformed KIBA values to the
equivalent of a pKi or pKd and include the transformed data
in RegenBase alongside the original values where they exist.
Figure 2. The generic event representation (a) for primary findings manually curated from the literature including provenance of the primary finding
statement. Classes are shown as yellow boxes, individuals/literals as blue rounded boxes and relations between them as labeled arrows. An example
event (b) in RegenBase specifies that the small molecule PD98059 was observed to increase BBB score by 4 points. Provenance for this event states
that it was created by Vance Lemmon on September 9 2015 and was sourced from an article with PubMed identifier 18180375.
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The neurite outgrowth assay data quantify the effects of
compounds on neurite outgrowth with respect to a control,
and are measured as the percentage of neurite total length
observed relative to neurite total length when exposed to a
control substance (dimethyl sulfoxide).
We used the BAO as well as the RB to represent assay
details and experimental results. We used the NASA Units
Ontology (UO) for all measurement units. We adopt BAO
representation conventions (27) for grouping related assay
results using the ‘Measure Group’ class, and use BAO
classes and properties where possible. Figure 3 illustrates
our assay representation approach with an example kinase
activity assay.
We linked all assay perturbagens (screened entities) and
kinase targets to their PubChem CIDs and UniProt protein
identifiers where possible, to enable integration of existing
publicly available data about these entities with
RegenBase. For example, in Figure 3 we illustrate the re-
sults of a kinase activity assay measuring the effect of a 10
lM concentration of compound A674563 (PubChem CID
11314369) on the activity of adaptor-associated protein
kinase 1 (human AAK1; UniProt ID Q2M2I8).
Data encoding and integration
We used the RDF, a World Wide Web Consortium stand-
ard for linked data, to encode the literature-sourced event
data and assay data that compose RegenBase. A.C. and
S.W.A. developed custom programs in Java and Python for
this purpose (available from the RegenBase website). We
loaded these RDF data into an instance of the Virtuoso
Open Source triplestore engine, version 7.10. RegenBase
can thus be queried using the SPARQL Protocol and RDF
Query Language (SPARQL) for fast data integration and
retrieval, including queries that leverage basic subsumption
reasoning and property paths, functionalities that are na-
tively enabled by Virtuoso Open Source. The use of OWL
ontologies as the backbone for organizing and structuring
the RDF linked data in RegenBase also enables reasoning
and consistency checking using a standalone reasoner such
as Pellet (28) or Konclude (29).
Statements resulting from literature curation were
manually reviewed by V.P.L., J.L.B. and A.C. for correct-
ness and consistency. A subset of each assay dataset in
RDF was also manually reviewed and compared with its
source dataset (as provided by the original study investiga-
tors) for correctness. We reviewed RDF data using the
Virtuoso Faceted Browser and SPARQL queries.
The use of publicly available identifiers for genes (from
NCBI Gene), proteins (from UniProt) and chemicals (from
PubChem) in RegenBase allows for automatic integration
of data across publications from the literature annotations
and across assay results. This enables the interrogation of
RegenBase to quantify the effect of perturbagens on SCI re-
covery across multiple studies and assay types with simple
queries, as we demonstrate in the following sections.
Figure 3. Example representation of assay experimental results using BAO, RB and UO. Classes are shown in yellow with their source ontology in
brackets and instances are in blue. All relations except ‘label’ (RDFS) and ‘has identifier’ (SIO) are sourced from BAO. Classes are shown as yellow
boxes (with the source ontology in brackets), individuals/literals as blue rounded boxes and relations between them as labeled arrows.
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Results
RB and contents
The RB consists of 435 classes, 18 object properties and 8
data properties. The ontology is publicly available for
search and download at NCBO’s BioPortal (see http://bio
portal.bioontology.org/ontologies/RB).
The current version of RegenBase contains statements
from 42 curated publications alongside the experimental
results of kinase activity assays and compound screening
assays for neurite outgrowth. Literature-sourced assertions
contribute approximately 20 000 statements and assay ex-
perimental results contribute approximately 15 million
statements.
The kinase assay data available in RegenBase capture
the reported effects of nearly 52 000 compounds on the
activity of 476 kinases, and the neurite outgrowth assay
data capture the effect of 1606 compounds on neurite
outgrowth in hippocampal neurons. We obtained kinase
activity data from five sources: a published
GlaxoSmithKline screen of kinase inhibition (30), a re-
cent study of kinase inhibitor polypharmacology (31),
two published studies of kinase inhibitor selectivity (32,
33) and one study that quantified kinase inhibitor select-
ivity by calculating an integrated activity measure from
the results of multiple kinase inhibitor selectivity assays
(26). The neurite outgrowth assay data are from two pub-
lished studies on screening assays to identify drug targets
that promote axon growth (31, 34).
The public RegenBase SPARQL endpoint and
linked data files are available at http://regenbase.org.
Both RegenBase and MIASCI are registered at
biosharing.org.
Querying RegenBase to identify potential targets
for SCI drug therapies
RegenBase automatically links in vivo data, such as behav-
ioral outcome measures associated with exposure to small
molecules, to in vitro biochemical profiling data that de-
scribe potential targets of those small molecules, such as
kinase inhibition profiles. From these links, researchers can
develop hypotheses about molecular mechanisms for com-
pounds that have observed behavioral effects.
By querying RegenBase, we have identified compounds
that have been reported to improve locomotion after SCI
(based on two open field outcome measures used in ro-
dents, the BBB and BMS tests) and that also have been
observed to strongly inhibit particular kinases in vitro. We
have also identified the in vitro targets of these com-
pounds, thereby offering insight into the mechanism(s)
underlying the observed behavioral effects. We performed
this task using a single query:
QUERY 1—What are the kinase targets of
perturbagens that have been observed to increase
BBB/BMS score and inhibit kinase activity with
either a % inhibition of at least 50% at a
perturbagen concentration of 0.1 lM or a pKd/pKi
of at least 7?
This query retrieves all events where the agent is a small
molecule and the target is a BBB or BMS score, where the
source article reported that the agent increased BBB/BMS
score. The agent must also have been observed to inhibit
kinase activity relative to a control, in at least one assay
measuring either percent inhibition (for which the thresh-
old is 50%) at a perturbagen concentration of 0.1 lM or
dissociation/inhibition constants (for which the threshold
of the corresponding log-transformed values is 7). The
query finds the identifiers of all compounds that satisfy
these constraints and their kinase targets from each kinase
activity assay, and returns the unique compound–kinase
target pairs. The SPARQL query is shown in
Supplementary Appendix S3; results are shown in Table 1.
The first compound, SB 415286, inhibits GSK3 beta, a
protein implicated in plasticity and sprouting. It has been
reported that conditional knockout of GSK3 beta increases
DRG axon regeneration and the sprouting of
5HTþ terminals after SCI (35). The result of this
RegenBase query linking inhibition of GSK3B to a positive
behavioral outcome in the BBB test is fully consistent,
therefore, with other studies linking GSK3B to axon
regeneration.
Fasudil is a known ROCK1/2 inhibitor, and its promo-
tion of axon regeneration is normally ascribed to these
activities. Fasudil has only modest effects on neurite
growth for neurons on permissive substrates (34), but
strongly promotes neurite growth on inhibitory substrates
(36, 37).The biochemical profiling data queried by
RegenBase reveal that Fasudil also inhibits PRKX, a pro-
tein recently identified as an important target for kinase in-
hibitors promoting axon growth (31). Thus, Fasudil’s
growth promoting activity in vitro, and reported ability to
improve behavioral outcomes in vivo, could both result
from inhibiting PRKX together with ROCKs, and this
‘positive polypharmacology’ makes it an attractive candi-
date for treatment of SCI.
PD 168393 is an epidermal growth factor (EGF) recep-
tor inhibitor and has been used in several SCI studies,
including the NINDS SCI replication project (38–43). PD
168393 has been shown to increase neurite growth in vitro
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(e.g., Refs 44 and 45). Query results from RegenBase iden-
tify EGFR as well as ERBB proteins as strongly inhibited
targets of PD 168393. However, knocking down EGFR
does not promote neurite growth, suggesting that PD
168393 acts on targets other than (or in addition to) neur-
onal EGFRs, either EGFRs on other cell types or other mo-
lecular targets on neurons (46). ERBB2 has no ligand
binding domain of its own but forms heterocomplexes
with other ERBB family members; ERBB4 binds neuregu-
lins and its activation positively regulates neurite growth
(45). This suggests that PD 168393’s ability to improve
BBB score is not owing to its inhibition of EGFRs/ERBBs
on neurons; perhaps, the relevant effects are on glial
receptors.
Finally, SB 203580, typically reported as a p38 kinase
inhibitor, inhibits a large number of kinase targets, many
of which are relevant to axon growth. Improvement in be-
havioral outcomes following SCI in animals treated with
SB 203580 has been attributed to p38 kinase inhibition
(47). However, our recent work implies that both p38-
alpha (mitogen-activated kinase MAPK14) and p38-beta
(MAPK11) are ‘anti-targets’, whose inhibition should be
avoided in order to promote axon growth in hippocampal
neurons (31). This conclusion is in line with previous sug-
gestions that p38s are positive regulators of neurite
growth, and that inhibition of p38 activity suppresses
growth promotion through Nerve Growth Factor (48–50).
Results of our queries to RegenBase suggest an alternative
mechanism for SB 203580: it inhibits both JNK3 and
Casein Kinase 1 (CSNK1A1, CSNK1D and CSNK1E),
which are negative regulators of axon growth. This
suggests that inhibition of JNK3 and CSNK1s by SB
203580 enhances axon growth. Perhaps, therefore, JNK3
and the CSNK1s are the targets of SB 203580 mediating
the reported positive behavioral outcomes in vivo. An al-
ternative explanation is that SB 203580 exerts its in vivo
effect by acting on cells other than neurons (see Ref. 31).
The above query illustrates how RegenBase enables the
progression of inquiry from a general question about
in vivo studies and high throughput screening data to spe-
cific hypotheses about novel targets and compounds that
could be tested in vitro or in vivo. For example, does
knocking out or knocking down PRKX in neurons in vivo
enhance axon regeneration, or improve behavioral out-
comes after CNS injury? The literature offers conflicting
information about the role of p38/MAPK in axon regener-
ation. SB 203580 is used as a p38 (MAPK11 and MAP14)
inhibitor and this is reported to enhance optic nerve regen-
eration (51). In contrast, MAPK14 loss of function leads to
reduced axon regeneration in a sciatic nerve crush model
(52). It seems likely that SB 203580 promotes optic nerve
regeneration by acting either on a non-p38 target in retinal
ganglion cells (RGCs) or on p38s in other cell types such as
Mu¨ller cells or astrocytes, to help RGCs survive or regener-
ate. RegenBase provides a ‘tool for thought’ to arrive at
these novel biological hypotheses (53), which we plan to
test experimentally.
Querying RegenBase to identify drugs of interest
In this section, we present two additional examples of
using RegenBase to identify perturbagens of interest to the
SCI research community. RegenBase allows researchers to
aggregate experimental findings across published studies,
and to use the RB class hierarchy to identify related behav-
ioral outcome measures widely used to assess functional re-
covery following SCI in mouse and rat models.
QUERY 2—What perturbagens have been
observed to improve behavioral outcomes
following injury?
QUERY 2 retrieves all events where the target is of type
‘outcome measure’ or any of its subclasses, and where the
agent is of type ‘small molecule’ and has an ‘increase’ effect
on the target. It returns the distinct set of compound identi-
fiers of the agent. The SPARQL query is shown in
Supplementary Appendix S3; Table 2 shows the com-
pounds returned by this query with their names.
QUERY 2 leverages the class hierarchy of RB to ask for
data about any behavioral outcome (entities that are in-
stances of any subclass of the RB class ‘behavioral out-
come’, RB_0008016). This kind of query allows one to
Table 1 . Kinase targets that are strongly inhibited by com-
pounds that have been independently observed to improve
BBB score following injury
Perturbagen
(with PubChem identifier)
Kinase targets strongly inhibited
(with UniProt identifier)
SB 415286 (4210951) GSK3B (P49841)
Fasudil (3547) PRKX (P51817),
ROCK2 (O75116),
PRKACA (P17612)
PD 168393 (4708) EGFR (P00533), ERBB2
(P04626), ERBB4 (Q15303)
SB 203580 (176155) CSNK1A1 (P48729), CSNK1D
(P48730), CSNK1E (P49674), GAK
(O14976), JNK3 (P53779),
MAPK11/p38-beta (Q15759),
MAPK12 (P53778), MAPK13
(O15264), MAPK14/p38-alpha
(Q16539), NLK (Q9UBE8),
RIPK2 (O43353)
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quickly identify treatments that could be used in combin-
ation to look for synergistic effects of compounds in vitro
or in vivo.
QUERY 3—What perturbagens have been
observed to improve BBB or BMS score following
injury and also to increase neurite outgrowth?
How many assay results report the neurite
outgrowth effect? How many articles report the
BBB/BMS score effect?
QUERY 3 retrieves all events where the agent is a small
molecule and the target is a BBB or BMS score, where the
curated source article reported that the agent increased
BBB or BMS score. An additional constraint is that the
agent must also have been observed to increase neurite out-
growth relative to a control, in at least one separate assay
(of type ‘neurite outgrowth assay’, from the BAO). The
query returns the identifiers of all agents that satisfy these
constraints as well as the number of assay results reporting
the effect on neurite growth and the number of articles re-
porting the effect on BBB/BMS score. The SPARQL query
is shown in Supplementary Appendix S3; query results are
shown in Table 3.
A large variety of treatments are tested in vivo for im-
proving various behavioral outcomes after SCI. For ex-
ample, some treatments, such as the CDK inhibitor CR8,
are hypothesized to improve pain management by reducing
microglial activation. This search result indicates that the
treatment could also be directly influencing neurons, per-
haps by altering sprouting after injury. Therefore,
RegenBase can easily allow the generation of new hypothe-
ses about cellular targets for various treatments that can be
subsequently investigated.
Discussion
To our knowledge, RegenBase is the first publicly available
resource that structures and automatically integrates SCI
domain knowledge with literature-sourced and raw experi-
mental data. This work marks an important step forward
in applying informatics tools and methods to drive discov-
eries in SCI research. With its current focus on regener-
ation, RegenBase enables the formulation of hypotheses
about potential drug targets, and how they may improve
recovery after SCI.
Although we were successful in the technical exercise of
integrating literature sourced reports of experimental ob-
servations with relevant assay data, and structuring this in-
formation with a domain ontology to facilitate querying,
our approach has several limitations. One of the primary
challenges in developing RegenBase is the technical know-
ledge required to develop and implement data representa-
tion schemes, as well as to use query languages such as
SPARQL for interrogation. The technical expertise
required for developing RegenBase is not unique to this
project—all biomedical databases rely on expert architects
and administrators to create and maintain them over time.
As the adoption of Semantic Web standards for structuring
and querying data on the web continues to increase, so too
does the availability of resources designed to instruct and
aid both the experienced developer and the new user (e.g.
Ref. 54). Recent work has also focused on developing user-
friendly tools for constructing SPARQL queries that auto-
suggest types and predicates to lower the barrier to use,
e.g. Ref. 55, or that allow users to define queries using a
controlled natural language which are then converted to
Table 3. Compounds that have been experimentally observed
to improve BBB or BMS score following injury and which
have independently been observed to increase neurite
outgrowth
PubChem identifiers.org
identifier
Name Number
of assays
Number
of articles
http://identifiers.org/pubchem.
compound/10224714
CR8 2 2
http://identifiers.org/pubchem.
compound/3547
Fasudil 1 4
Table 2. The identifiers and names of 18 compounds that
have been experimentally observed to improve behavioral
outcomes following SCI
PubChem identifiers.org identifier Name
http://identifiers.org/pubchem.compound/5957 Adenosine
triphosphate
http://identifiers.org/pubchem.compound/2046 AG 126
http://identifiers.org/pubchem.compound/5328775 AG 556
http://identifiers.org/pubchem.compound/72941992 AM 111
http://identifiers.org/pubchem.compound/9813758 BMS 345541
http://identifiers.org/pubchem.compound/10224714 CR8
http://identifiers.org/pubchem.compound/3547 Fasudil
http://identifiers.org/pubchem.compound/6324617 Ginkgolide B
http://identifiers.org/pubchem.compound/3973 LY 294002
http://identifiers.org/pubchem.compound/6741 Methylpre-
dnisolone
http://identifiers.org/pubchem.compound/4708 PD 168393
http://identifiers.org/pubchem.compound/4713 PD 98059
http://identifiers.org/pubchem.compound/126402 PRE 084
http://identifiers.org/pubchem.compound/5040 Rapamycin
http://identifiers.org/pubchem.compound/176155 SB 203580
http://identifiers.org/pubchem.compound/4210951 SB 415286
http://identifiers.org/pubchem.compound/4124851 TDZD-8
http://identifiers.org/pubchem.compound/3006531 U0126
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SPARQL on the fly, e.g. Ref. 56. Front-end search inter-
faces that provide an entry point to biochemical data struc-
tured using ontologies, such as the LINCS Information
Framework (LIFE) project (57) (see http://life.ccs.miami.
edu/life/), also make resources like RegenBase accessible to
a broader user base.
The manual effort and domain expertise required for lit-
erature curation is another limitation in developing re-
sources such as RegenBase. Our curators estimate that
curating one publication requires between 1 and 3 h. We
are mitigating this by developing an online tool for litera-
ture curation using MIASCI as its backbone, which is pub-
licly available at http://regenbase.org/miasci-online.html.
Our aim is to streamline the process for SCI researchers to
curate their own research as it is published, and also to cur-
ate previously published work. Assessing the scalability of
our curation and data collection approach as well as the ef-
fect of inter-curator variability is a multi-year effort, but
one that will be possible as curators and users contibute
data to RegenBase over time.
Crowdsourcing approaches have also shown great prom-
ise in reducing the overhead of manual curation.
Crowdsourcing biocuration tasks via online platforms such
as Amazon’s Mechanical Turk (where workers are paid for
completing tasks) produces both accurate and comprehen-
sive results (58, 59). Crowdsourcing curation of abstracts to
identify a limited set of SCI experimental metadata such as
the animal models, injury types and perturbagens studied as
well as primary observed outcomes would be an exciting po-
tential advance for RegenBase. Our hypothesis is that the
sheer scale of such crowdsourced curated data will outweigh
potential inaccuracies introduced by the variation in worker
ability and domain knowledge. However, selecting success-
ful tasks and incentives for crowdsourcing is a research area
in itself, and far from a solved problem. The success of the
endeavor will also depend on the quality of available ab-
stracts, and we believe that initially such crowdsourced data
should augment, but not replace, a smaller but richer know-
ledge base constructed by experts curating entire published
research papers.
Crowdsourcing approaches to populate RegenBase
would benefit greatly from community incentives to re-
ward the effort of curating literature and making experi-
mental data publicly available. A data publishing platform
allowing scientists to get credit for sharing their data
(including negative results) and also to cite data they use in
their research or contribute to resources like RegenBase
would offer just such an incentive. A system by which to
track scientific contribution by data publishing would also
advance the scientific community as a whole by encourag-
ing researchers to make their data publicly available and
by making the collection of ‘altmetrics’ for scientific
contribution (such as dataset downloads and reuse) pos-
sible. Newer forms of publication venues, such as the jour-
nal Nature Scientific Data, make such an incentive scheme
feasible.
The data representations we have developed to struc-
ture reported experimental results for RegenBase offer sev-
eral advantages. Firstly, they capture different types of
experimental data from a variety of sources in a consistent
manner, making query formulation easier. For example, a
query to retrieve kinase percent inhibition screening data
needs to be modified only slightly to retrieve kinase pKd/
pKi data. As RegenBase continues to grow (we are continu-
ally adding literature-sourced statements and experimental
data), it will be increasingly important to be able to reuse
our existing data representations (and the code that imple-
ments them) to maintain a scalable workflow.
Secondly, our use of a consistent identifier scheme when
creating linked data from different sources enables auto-
matic linking of assay experimental results to each other
and to literature-sourced data, as demonstrated by the
queries presented above. Our use of identifiers.org URIs
automatically links RegenBase statements to the larger
public linked data network of biological and biochemical
resources which provide additional information about the
genes, proteins, and chemicals in RegenBase (60–63). This
offers the potential to perform analyses using RegenBase
alongside additional sources, such as information about
protein family relationships, other biochemical profiling
data, GO annotations, and model organism specific data-
bases such as the Mouse Genome Informatics database
(64) and Rat Genome Database (65, 66) to make add-
itional discoveries and develop new hypotheses for experi-
mental testing.
Finally, the data representations we developed consider
all reported events and assay results as contextually true
within the scope of the source publication or dataset, but
purposely make no claims as to their global truth. One of
our aims for RegenBase is to allow its users to identify
contradictory facts and data across publications, a task that
if undertaken manually would require hours of reading and
data integration. By allowing potentially contradictory data
to coexist in RegenBase, a simple query allows users to iden-
tify such cases. In future work, we will explore methods for
automatically identifying contradictory data, as well as
approaches for displaying or flagging such data for users.
Domains that are closely related to SCI, such as trau-
matic brain injury (TBI) and optic nerve regeneration,
would also benefit from RegenBase’s structured representa-
tion of experimental data and literature findings. Efforts to
develop Common Data Elements for describing preclinical
TBI experiments (67) mirror our work on RegenBase and
set the stage for extending RegenBase to the domain of TBI.
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The high prevalence of glaucoma and resulting optic nerve
injuries has inspired a significant effort to identify gene tar-
gets and therapeutics to promote optic nerve regeneration,
e.g. Refs 68 and 69. Importantly, there is also a significant
overlap in protein targets such as phosphatase and tensin
homolog (70, 71) and Kru¨ppel-like factors (72, 73) in optic
nerve and spinal cord axon regeneration. The ability to
query a knowledge base across these disparate domains
could speed hypothesis generation and testing in both areas.
In conclusion, we have developed RegenBase, a know-
ledge base for SCI biology. We have demonstrated its use
to answer domain-specific questions and develop biolo-
gical hypotheses by computationally aggregating facts and
data from multiple sources. RegenBase is publicly available
at http://regenbase.org. Its use by the scientific community
and resulting feedback will allow us to continue to develop
and extend the functionality of this resource.
Supplementary data
Supplementary data are available at Database Online.
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